Abstract:PURPOSE:A new chemotherapy regimen was designed for leukemia to improve response to therapy and elucidate the possible underlying mechanisms responsible for its efficacy.METHODS:Cells of the chronic myelogenous leukemia (CML) cell line, K562, were treated singly, in combination, and in sequence with clinically equivalent dosages of topotecan, which targets topoisomerase I (Topo I), and etoposide and mitoxantrone, which target topoisomerase II (Topo II), to determine the best treatment. Apoptosis, early cell deaths, and cell cytotoxicities in drug-treated cells were determined with annexin V and propidium iodide staining and MTT assays, respectively. Confocal microscopy and RT-PCR showed the cellular locations and relative increases in Topo IIalpha in topotecan-treated cells. The double comet assay of individual cells showed simultaneously free Topo proteins, non-Topo-associated DNA, and Topo-DNA complexes in drug-induced DNA fragments.RESULTS:Sequential treatment with topotecan on days 1-3, followed by etoposide+mitoxantrone on days 4, 5, 9 and 10 resulted in 100% cell death whereas treatments involving administration of drugs singly or simultaneously resulted in less cell kill. The cytotoxicity results in cells treated for fewer days with the same sequential chemotherapy regimen showed the same trend, and adequate surviving cells for the experiments on the cellular and molecular mechanisms of drug action were produced. An increase in Topo IIalpha mRNA from RT-PCR 1 h after topotecan treatment was observed. Observations on K562 cells treated sequentially with topotecan followed by etoposide, mitoxantrone or etoposide+mitoxantrone were as follows: (1) Topo IIalpha protein levels increased and relocated from the cytoplasm into the nucleus as detected by confocal microscopy, (2) Topo IIalpha-DNA complexes increased and were associated with fragmented DNA (positive double comets) as detected by protein-DNA double comet assay, and (3) Topo I and Topo IIbeta proteins were not associated with fragmented DNA. Topotecan-induced Topo IIalpha protein levels correlated with increased numbers of positive double comets and reduction of cell viability.CONCLUSIONS:Our results showed that Topo IIalpha protein induction after Topo I-directed drug treatment enhanced the sensitivity of cells to subsequent exposure to Topo II-directed drugs. Timed sequential chemotherapy with topotecan followed by etoposide+mitoxantrone is an effective regimen to ablate CML cancer cells.

The study of killing and proapoptotic effects of topoisomerase Ⅰ inhibitor on L1210/ADM cells

[Inhibition Effect of Topotecan on Human Myelodysplastic Syndrome Cells in Vitro and in Vivo].

[Killing and Proapoptotic Effects of Topoisomerase I Inhibitor on K562 Cells].

Influence of inhibitor of signal transduction on the cell apoptosis induced by TNF β

A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell.

[Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Acute T-Lymphoblastic Leukemia Jurkat Cells in Vitro and Its Possible Mechanisms].

Topotecan induces caspase-dependent apoptosis in HL-60 cells

The Study of Topotecan Induced Apoptosis in Cisplatin-resistant Human Ovarion Cancer Cell Lines COCl/DDP

Study about the mechanism of low dose topotecan on lung cancer cell lines HTB-56/DDP with brain metastasis

Effect of Topotecan on Apoptosis of HL-60 Cells

Molecular Mechanism of Apoptosis in Cisplatin-Resistant Human Ovarian Cancer Cell Lines Promoted by Topotecan

Attenuation of Drug-Stimulated Topoisomerase Ii Dna Cleavable Complex Formation in Wild-Type Hl-60 Cells Treated with an Intracellular Calcium Buffer is Correlated with Decreased Cytotoxicity and Site-Specific Hypophosphorylation of Topoisomerase Ii Alpha

Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.

A Novel Dna Topoisomerase I Inhibitor with Different Mechanism from Camptothecin Induces G2/M Phase Cell Cycle Arrest to K562 Cells

Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors.

Topotecan-induced Topoisomerase IIalpha Expression Increases the Sensitivity of the CML Cell Line K562 to Subsequent Etoposide Plus Mitoxantrone Treatment.

Apoptosis of HL60/VCR Cells Induced by Topotecan

The Antitumor Activity of CYB-L10, a Human Topoisomerase IB Catalytic Inhibitor.

Synthesis and Biological Activities of 11-and 12-Substituted Benzophenanthridinone Derivatives As DNA Topoisomerase IB and Tyrosyl-DNA Phosphodiesterase 1 Inhibitors

Natural inhibitors of DNA topoisomerase I with cytotoxicities.

Synthesis and evaluation of the apoptosis inducing and CT DNA interaction properties of a series of 4β-carbamoyl 4'-O-demethylepipodophyllotoxins.